Joshua Bauml
Medical Oncology · Philadelphia, PANPI 1740449487
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $109,113 of the $144,221 with a category attached, or 75.7%. It is spread thinly across 22 manufacturers, the largest accounting for just 23.3%. Reporting peaked in 2019 at $55,514 and has fallen 87.9% since, to $6,690 in 2022. Among medical oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $1413.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$34K
- Genentech USA, Inc.$15K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- E.r. Squibb & Sons, L.L.C.$11K
- Amgen$11K
- Novartis$11K
- plus $50K from 16 others
Across 117 payments — averaging $44,096 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.7M
- Takeda Pharmaceuticals U.S.A., Inc.$908K
- Amgen$869K
- AstraZeneca$719K
- Pfizer$622K
- Merck$335K
- plus $45K from 1 others
What the payments were for
- Consulting fees$109,11376%
- Speaking & faculty fees$19,35013%
- Travel & lodging$12,4879%
- Food & beverage$1,7721%
- Education$1,5001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $33,605 |
| Genentech USA, Inc. | 16 | $15,323 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $12,313 |
| E.r. Squibb & Sons, L.L.C. | 10 | $11,436 |
| Amgen | 4 | $11,058 |
| Novartis | 4 | $10,938 |
| Astrazeneca UK Limited | 9 | $9,105 |
| Daiichi Sankyo Inc. | 3 | $8,503 |
| Merck | 4 | $5,555 |
| Janssen Scientific Affairs, LLC | 4 | $4,040 |
| Agilent Technologies, Inc. | 3 | $3,866 |
| Regeneron Healthcare Solutions, Inc. | 3 | $3,150 |
| Johnson & Johnson | 1 | $3,090 |
| Regeneron | 1 | $2,360 |
| Bayer | 1 | $2,280 |
| Foundation Medicine, Inc. | 1 | $1,750 |
| Janssen Global Services, LLC | 1 | $1,550 |
| Ipsen Biopharmaceuticals, Inc | 1 | $1,500 |
| Eli Lilly | 1 | $1,400 |
| Boehringer Ingelheim | 2 | $1,300 |
| Genentech, Inc. | 1 | $79 |
| Incyte Corporation | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$144,221 in reported general payments places this provider in the 90th percentile of 238 medical oncology providers in Pennsylvania.
Other medical oncology in Philadelphia
- Carl JunePhiladelphia$9M
- Shayma KazmiPhiladelphia$619K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Edith MitchellPhiladelphia$220K
- Elizabeth PlimackPhiladelphia$190K
- Alexander PerlPhiladelphia$176K
- Martin EdelmanPhiladelphia$157K
- Jean-Pierre IssaPhiladelphia$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.